GHK-Cu Cardiovascular Impact Long-Term: What the Evidence Actually Shows

Is there any human evidence that GHK-Cu affects the heart or blood vessels?

We found no study that gave GHK-Cu to people and measured a cardiac or vascular endpoint. The human randomized trials located are topical, with 13 and 86 patients [1][2]. A 2026 systematic review of the GHK-Cu literature, which retained 64 records after screening, describes the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [8].

What the two human trials measured

Copper tripeptide after CO2 laser resurfacing (Miller 2006). Thirteen patients completed a randomized trial in which skin around the mouth was resurfaced with a CO2 laser, then treated with or without GHK-Cu skin care. Computer analysis and blinded evaluators found no significant difference between groups in how quickly redness resolved, in wrinkles, or in overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [1].

Venous stasis ulcers (Bishop 1992). Eighty-six evaluable patients were randomized and evaluated blindly. A 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo for ulcer size, while silver sulfadiazine 1% did reduce ulcer size [2].

What the mechanism research covers

GHK is a tripeptide found in human plasma, saliva and urine, with levels reported to decline with age; the authors of the main review propose that it works as a complex with copper. That review, written by the researchers who proposed GHK as a therapeutic peptide, reports that GHK stimulates both synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinases and their inhibitors, attracts immune and endothelial cells to injuries, and speeds wound healing in dogs, rats, mice and pigs. These are proposed mechanisms from laboratory and animal work, not proven human effects, and the review is about skin regeneration [4].

What FDA says about injectable GHK-Cu

FDA lists GHK-Cu for injectable routes in the 'nominated but withdrawn' table of bulk substances that may present significant safety risks. Its stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3].

Non-injectable GHK-Cu sits in category 1 of FDA's interim policy for state-licensed pharmacies and physicians; FDA intends to consult its Pharmacy Compounding Advisory Committee about it before the end of February 2027, and no vote has happened yet [5][9]. No FDA-approved drug is known to contain GHK-Cu [5][6], and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [11].